Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Far Eastern Memorial Hospital

Status: Enrolling

Conditions: Overactive Bladder Syndrome

Treatments: Drug: Solifenacin Oral Tablet; Drug: Mirabegron 25mg

Study type: Observational

Funder types: Other

Identifiers

NCT05040984

110053-E

Details and patient eligibility

About

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Enrollment: 500 estimated patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with overactive bladder syndrome received solifenacin or mirabegron as the initial treatment

Exclusion criteria

• <20 year-old

Trial design

500 participants in 2 patient groups

solifenacin

Treatment:

Drug: Solifenacin Oral Tablet

mirabegron

Treatment:

Drug: Mirabegron 25mg